We are on a mission to improve patient care with regenerative biomaterials that are inspired by nature.
Vascudyne™
Developing, manufacturing and commercializing regenerative acellular in-vitro grown “allograft” tissue.
TRUE to Nature™ Biomaterials
Discover the benefits of using 100% biological soft tissue implants and how the investigational TRUE™ Tissue technology is poised to revolutionize healthcare.
Announcing First in Human Use of TRUE™ Graft for Hemodialysis
PRECLINICAL PERFORMANCE
Cellular infiltration and tissue regeneration
No evidence of thrombosis or intimal hyperplasia
Successful 6-month AV graft study in baboons
BIOLOGICAL
Naturally derived extracellular matrix
No crosslinking or other chemical fixation
No synthetic materials used through entire manufacturing process
Mechanical
Predictable and tunable anisotropic tensile properties
High suture retention, capable of sewing into valve frames
Excellent post-implantation flow profiles of AV grafts in First in Human clinical study
News
Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury
Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference
Regenerative Medicine Company Vascudyne Relocates to High Capacity GMP Manufacturing Facility
Vascudyne’s TRUE Tissue Technology is a Top 3 2022 Better World Project Award Finalist
Regenerative Medicine Company Vascudyne Closes $10 Million Series A Financing
Vascudyne announces successful First Human Use of TRUE™ Vascular Graft for hemodialysis access
Vascudyne’s CSO presents at the Heart Valve Society Meeting on tissue remodeling of engineered valved conduit evaluated at 52 weeks in the growing lamb
Lab-created heart valves can grow with the recipient article published in Science Translational Medicine
Proud Member of:
Copyright 2021 | Vascudyne, Inc.
